The Role for Tocilizumab in COVID-19 Patients: Reflections on Monza Cohort Data

Figures & data

Table 1 Baseline Characteristics of Patients

	Tocilizumab (N = 31)	Standard of Care (N = 44)	Overall (N = 75)
Characteristics
Age (years*)	59 (54–68)	61 (57–69)	59 (57–68)
Sex*
Male	27 (87%)	38 (87%)	65 (87%)
Female	4 (13%)	6 (13%)	10 (13%)
Baseline WHO Class*
4	1 (3%)	1 (2%)	2 (3%)
5	25 (81%)	36 (82%)	61 (81%)
6	5 (16%)	7 (16%)	12 (16%)
Duration of Symptoms* (Days from Onset to Hospitalization)	7 (5–10)	8 (6–10)	7 (6–10)
Comorbidities
Hypertension	14 (45%)	21 (49%)	35 (47%)
Cardiovascular Disease	4 (13%)	8 (19%)	12 (16%)
Diabetes	2 (6%)	13 (30%)	15 (20%)

Notes: Results are reported as number (%) or median (I–III quartile); *matching factors.

Figure 1 Mortality rate in 60 days from hospital admission (standard Kaplan–Meier in the tocilizumab group and weighted Kaplan–Meier in the matched sample).

Abbreviation: se, standard error.